Related Experiment Video
Updated: Jan 11, 2026
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
Dual-channel six-step linear concentration gradient microfluidic chip for orthogonal combination drug screening in
Jingru Liao1,2, Zhimi Zhang3,2, Guiquan Zhu4
1Department of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract:
Head and neck cancer, as the seventh most common cancer worldwide, is in urgent need of an efficient drug screening platform due to tumor heterogeneity and the lack of objective markers for conventional chemotherapy resulting in limited efficacy. In this study, we developed a dual-channel microfluidic chip integrating organoid technology and hydrodynamic modulation, and realized six-chamber linear drug concentration gradient generation (<3% fluctuation at a flow rate of 10-100 μL min-1, stable for 24 hours) through a three-layer PDMS structure and serpentine microchannel design. After 24 h of treatment with four drugs, CAL-27 cell viability in the chip decreased with increasing drug concentration, showing no significant difference from conventional assays. Using a Matrigel 3D scaffold, the culture time of spheroids was reduced by 24 h compared with monolayer cells, and the organoid morphology remained unchanged before and after drug addition (P > 0.05). Fluorescence staining revealed distinct responses to the four drugs near their IC50 concentrations (P < 0.01). The platform integrates fluorescence imaging and CFD simulation, which has the advantages of automation, high mimicry and low consumables compared with the off-chip method, providing a reliable tool for the optimization of the precision treatment plan for head and neck cancer.
Insights
A novel microfluidic chip integrates organoid technology for head and neck cancer drug screening. This platform offers a reliable tool for optimizing precision treatment plans by mimicking tumor environments.
Area of Science:
- Biomedical Engineering
- Oncology
- Drug Discovery
Background:
- Head and neck cancer is a major global health challenge.
- Tumor heterogeneity and limited chemotherapy efficacy necessitate advanced drug screening platforms.
- Current methods lack efficiency and objective markers for personalized treatment.
Purpose of the Study:
- To develop an efficient drug screening platform for head and neck cancer.
- To integrate organoid technology with microfluidics for high-fidelity drug testing.
- To enable precise generation of drug concentration gradients for accurate efficacy assessment.
Main Methods:
- Development of a dual-channel microfluidic chip with a three-layer PDMS structure.
- Generation of stable, linear drug concentration gradients using serpentine microchannels.
- Utilizing Matrigel 3D scaffolds for rapid spheroid culture and drug response analysis.
Main Results:
- The microfluidic chip successfully generated stable drug gradients with <3% fluctuation.
- CAL-27 cell viability decreased with increasing drug concentrations, consistent with conventional assays.
- Organoid morphology was maintained, and distinct drug responses were observed near IC50 concentrations.
Conclusions:
- The developed platform provides a reliable, automated, and cost-effective tool for head and neck cancer drug screening.
- It offers high mimicry of the tumor microenvironment, aiding in precision treatment optimization.
- This technology advances personalized medicine approaches for head and neck cancer patients.
